Minneapolis, Oct. 25, 2017 (GLOBE NEWSWIRE) -- MINNEAPOLIS, OCTOBER 25, 2017 – Life Epigenetics, the insurtech subsidiary of GWG Holdings, Inc. (Nasdaq: GWGH), announced that Michael P. Curran has joined the company as a Senior Advisor to its management team. In this role, Curran will advise the company on business and vertical market development, legal strategy, operating infrastructure and its financial model.
The hiring of Curran, who has more than 25 years of experience in the insurance industry, comes at an important time for Life Epigenetics which recently unveiled its products and services at Insuretech Connect 2017. With two pilot programs underway with life insurance companies to best determine how its M-Panel predictive epigenetic technology can be applied to insurance products and services, the company sees tremendous opportunity to commercialize its epigenetic technology throughout the industry.
Life Epigenetics holds the exclusive license for lifespan-predictive technology developed at the University of California, Los Angeles (UCLA) for the life insurance industry.
“Michael Curran brings strong experience in guiding the development and introduction of new technology into the insurance and financial services industries,” said Jon Sabes, founder and Chief Executive Officer of Life Epigenetics. “His counsel and relationships are key to the execution of our strategic plan to commercialize our epigenetic technology to become a significant player in the insurance industry.”
Curran most recently served as President and CEO of Force Diagnostics, Inc., a leading international provider of FDA-approved rapid tests and infrastructure software for the insurance industry and other large vertical markets. Curran has more than 25 years of proven experience as a senior operating executive, corporate strategist and venture capitalist inside the financial services industry, with a specific focus on insurance.
As President of Quantitative Data Solutions (QDS), he directed the aggregation, development and commercialization of the use of prescription transaction history records and predictive analytics to quantify the use of those records in the Life Insurance underwriting process. QDS then built an automated underwriting engine, Velogica, that was subsequently purchased, with the data assets and imbedded models, by TransamericaRe/NYSE:AEG.
Curran has served as president of multiple analytics, software and services companies serving the insurance and financial services sectors, including Magnify Financial Services acquired by Choicepoint (NYSE: CPS; now NYSE: RLEX), Portage Re Holdings and Trinity Life Enterprises.
Curran is the former Director of Strategic Development for the Allstate Corporation (NYSE:ALL) with responsibility for managing its corporate venture capital portfolio, and negotiating strategic alliances on behalf of the firm. He holds a B.A. from Wittenberg University, an M.B.A. from the Kellogg School of Management at Northwestern University and is a member of the Economic Club of Chicago.
About Life Epigenetics, Inc.
Life Epigenetics is the insurtech subsidiary of GWG Holdings, Inc. (Nasdaq: GWGH) that is dedicated to creating new technology that is transformative to the way life insurance and financial services underwrite and deliver longevity-based products and services. The company’s “DNA methylation-based predictor of mortality technology,” exclusively licensed from the University of California, Los Angeles (UCLA), provides unprecedented new insight into longevity using the cutting edge science of epigenetics.
For more information about Life Epigenetics, Inc., visit www.lifeegx.com
To contact Michael Curran, firstname.lastname@example.org
About GWG Holdings, Inc.
GWG Holdings, Inc. (Nasdaq: GWGH) is a financial services company committed to transforming the life insurance industry through disruptive and innovative products and services. The company owns Life Epigenetics and GWG Life. GWG Life is developing a suite of new longevity-based products for consumers and financial advisors under the LifeCare Xchange (LCX). The LifeCare Xchange provides consumers owning life insurance with the opportunity to exchange their life insurance into products that can be used to pay for long-term care and meet other retirement financial needs. Life Epigenetics is developing transformative M-Panel epigenetic technology to disrupt traditional life insurance underwriting practices. Since 2006, GWG Life has provided seniors over $436 million in exchange value for their life insurance and, as of June 30, 2017, owns a portfolio of over $1.5 billion in face value of policy benefits.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/da7530cd-4e24-433c-b6e9-5efef3311a84
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2f7f6607-8309-465e-a555-07e2244c969d
Dan Callahan GWG Holdings Inc. 612-746-1935 email@example.com
Source: GWG Life